Dr Dinah Parums Patents
1) Inventors: Parums; Dinah (Cambridge, GB); Phillips; Stephen Charles (Kent, GB); Ridden; John (Kent, GB)
Assignee: Pfizer Inc. (New York, NY); Application No. 894743; Filed: June 28, 2001
Abstract The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
2) Inventors: Davies, Michael John; Huggins, Jonathan Paul; Parums, Dinah Velta.
Assignee:Pfizer Inc. (Groton, CT).Application No. 20050148585 (USPTO); Filed: 7th July, 2002.
Abstract: This invention relates to the use of cyclic guanosine 3′,5′-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of chronic wounds of a non-diabetic origin including in particular chronic venous ulcers, chronic decubitus (pressure sores) and arterial ulcers; and acute wounds.